HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis.

Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising agent in selectively killing tumor cells. However, TRAIL monotherapy has not been successful as many cancer cells are resistant to TRAIL. Chemotherapeutic agents, such as doxorubicin have been shown to act synergistically with TRAIL, but the exact mechanisms of actions are poorly understood. In this study, we performed high-throughput small interfering RNA screening and genome-wide gene expression profiling on doxorubicin-treated U1690 cells to explore novel mechanisms underlying doxorubicin-TRAIL synergy. The screening and expression profiling results were integrated and dihydroorotate dehydrogenase (DHODH) was identified as a potential candidate. DHODH is the rate-limiting enzyme in the pyrimidine synthesis pathway, and its expression was downregulated by doxorubicin. We demonstrated that silencing of DHODH or inhibition of DHODH activity by brequinar dramatically increased the sensitivity of U1690 cells to TRAIL-induced apoptosis both in 2D and 3D cultures, and was accompanied by downregulation of c-FLIPL as well as by mitochondrial depolarization. In addition, uridine, an end product of the pyrimidine synthesis pathway was able to rescue the sensitization effects initiated by both brequinar and doxorubicin. Furthermore, several other cancer cell lines, LNCaP, MCF-7 and HT-29 were also shown to be sensitized to TRAIL by brequinar. Taken together, our findings have identified a novel protein target and its inhibitor, brequinar, as a potential agent in TRAIL-based combinatorial cancer therapy and highlighted for the first time the importance of mitochondrial DHODH enzyme and pyrimidine pathway in mediating TRAIL sensitization in cancer cells.
AuthorsT He, S Haapa-Paananen, V O Kaminskyy, P Kohonen, V Fey, B Zhivotovsky, O Kallioniemi, M Perälä
JournalOncogene (Oncogene) Vol. 33 Issue 27 Pg. 3538-49 (Jul 03 2014) ISSN: 1476-5594 [Electronic] England
PMID24013224 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Biphenyl Compounds
  • Dihydroorotate Dehydrogenase
  • Pyrimidines
  • RNA, Small Interfering
  • TNF-Related Apoptosis-Inducing Ligand
  • brequinar
  • Doxorubicin
  • Oxidoreductases Acting on CH-CH Group Donors
  • pyrimidine
  • Uridine
Topics
  • Antineoplastic Agents (pharmacology)
  • Apoptosis (drug effects)
  • Biphenyl Compounds (pharmacology)
  • Cell Line, Tumor
  • Computational Biology
  • Dihydroorotate Dehydrogenase
  • Dose-Response Relationship, Drug
  • Doxorubicin (pharmacology)
  • Drug Resistance, Neoplasm (drug effects)
  • Gene Expression Profiling
  • Gene Silencing
  • Humans
  • Mitochondria (drug effects, metabolism)
  • Oxidoreductases Acting on CH-CH Group Donors (antagonists & inhibitors, deficiency, genetics)
  • Pyrimidines (biosynthesis)
  • RNA, Small Interfering (genetics)
  • TNF-Related Apoptosis-Inducing Ligand (metabolism)
  • Uridine (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: